MetXia-P450

MetXia-P450 is a retroviral gene therapy designed to deliver the human cytochrome P450 2B6 (CYP2B6) gene directly into tumor cells. The therapy utilizes a recombinant retroviral vector encoding CYP2B6, along with marker genes (lacZ and neomycin resistance), to allow local conversion of the prodrug cyclophosphamide into its active, cytotoxic metabolites within tumor tissue. This gene-directed enzyme prodrug therapy (GDEPT) aims to enhance anti-tumor effects and limit systemic toxicity by activating chemotherapy selectively at the tumor site. The developer is Oxford Biomedica. It has been studied primarily in breast cancer and melanoma cutaneous tumor nodules and has shown evidence of gene transfer, local prodrug activation, and occasional partial responses or disease stabilization in early-phase trials. Clinical progress has not extended beyond phase II as of 2025[1][2][4][5][6][7].

Brand names

MetXia-P450MetXia-P-450MetXia-P 450

Other names

MetXia-P450MetXia-P-450MetXia-P 450MetXiaMetXia gene therapyMetXia-MG